Corestemchemon Has Done Administering Neuronata-R to Patients in Phase 1 to Extend the Validity of Its Drug.

2023.12.19

Pay Attention to Neuronata-R of Corestemchemon -- Mesenchymal Stem Cell Treats Amyotrophic Lateral Sclerosis (ALS)

2023.12.19

Relyvrio, Tofersen, and More Drugs for ALS? Corestemchemon is also drawing attention.

2023.12.19

Corestem Shares Protocol for Long-term NeuroNata-R Trial

2023.12.14

Korean Corestem Targets US Market for Ground-Breaking ALS Treatment

2023.12.14

First licensed stem cell therapy for ALS

2023.12.14

Neuronata-R® Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway

0000.00.00